Close Menu
  • Entertainment
    • Celebrities
    • Music
    • Television & Movies
  • Healthcare
    • Fitness
    • Health
    • Wellbeing
  • Lifestyle
    • Culture
    • Love
    • Trending
  • Living
    • Homes
    • Nice house
  • Style & Beauty
    • Accessories
    • Beauty
    • Fashion
  • Travel
    • Activities
    • Food
    • Places & Attractions
    • Weekend escapes
Facebook X (Twitter) Instagram
Sunday, June 22
  • Homepage
  • Sitemap
Facebook X (Twitter) LinkedIn VKontakte
Healthcare, Lifestyle, Entertainment, Living and TravelHealthcare, Lifestyle, Entertainment, Living and Travel
Banner
  • Entertainment
    • Celebrities
    • Music
    • Television & Movies
  • Healthcare
    • Fitness
    • Health
    • Wellbeing
  • Lifestyle
    • Culture
    • Love
    • Trending
  • Living
    • Homes
    • Nice house
  • Style & Beauty
    • Accessories
    • Beauty
    • Fashion
  • Travel
    • Activities
    • Food
    • Places & Attractions
    • Weekend escapes
Healthcare, Lifestyle, Entertainment, Living and TravelHealthcare, Lifestyle, Entertainment, Living and Travel
Home»Healthcare»MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts
Healthcare

MoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalysts

08/27/20241 Min Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

[ad_1]

Biopharma firm MoonLake Immunotherapeutics (NASDAQ:MLTX) was downgraded to Peer Perform from Outperform at Wolfe Research, citing concerns on overpromised timelines.

MLTX down about 2% premarket.

“Lacking near-term catalysts, MLTX is expected to lay dormant, especially with HS volume slowdown. Wolfe sees downside risk from potentially overpromised timeline.

Over the next 2–3 quarters, Wolfe expects MLTX to trade in tandem with the XBI index (I.E. between $40 and $55 assuming no biotech bull run),” Wolfe mentioned in an announcement.

The analysis agency mentioned that it could be fallacious on this downgrade ought to an M&A happen over the subsequent ~12-18 months, but it surely believes MLTX now not matches the mould of ‘pharma M&A goal’.

“A better time to re-evaluate MLTX would be ~Q1/Q2 2025 if MLTX meets the enrollment target (likely no rewards for meeting this timeline but could be penalized for delays). Though Wolfe is bullish on product POS, it finds the near term setup less favorable,” it provides.

The firm has a Hold suggestion in response to SA quant system, and the inventory has fallen about 17.6% YTD.

[ad_2]

Source: Seekingalpha

catalysts concerns downgraded Immunotherapeutics lack MoonLake nearterm
Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleBiotech company Scorpius records threefold rise H1 income, secures $14.4M financing
Next Article Premier Inc rating downgraded on FY25-26 guidance miss at Benchmark (NASDAQ:PINC)

Related Posts

Trump cuts UC health research in DEI purge

04/10/2025

Special needs dentists open more CA clinics with new grants

04/09/2025

How Medicaid cuts would threaten California mental health system- CalMatters

04/08/2025
Latest Posts

≡ The Unspoken Struggles of a Royal Childhood 》 Helitra.com

04/15/2025

Trump cuts UC health research in DEI purge

04/10/2025

Special needs dentists open more CA clinics with new grants

04/09/2025

How Medicaid cuts would threaten California mental health system- CalMatters

04/08/2025

Newsom administration misses Prop. 35 Medi-Cal rate deadline

04/02/2025
Highlights

≡ The Unspoken Struggles of a Royal Childhood 》 Helitra.com

04/15/2025

[ad_1] While many of us dream of being royalty as kids, the truth is that…

Trump cuts UC health research in DEI purge

04/10/2025

Special needs dentists open more CA clinics with new grants

04/09/2025

How Medicaid cuts would threaten California mental health system- CalMatters

04/08/2025
Copyright © 2023. Designed by Helitra.com.
  • Home
  • Entertainment
  • Healthcare
  • Lifestyle
  • Living
  • Style & Beauty
  • Travel

Type above and press Enter to search. Press Esc to cancel.